Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

To test for immunologic memory after a single dose of meningococcal C conjugate (MCC) vaccine in toddlers, 226 children 12-18 months old were randomized to receive 1 of 3 MCC vaccines, with a C polysaccharide booster 6 months later. The protein conjugate was diphtheria mutant toxoid in 2 vaccines (MCC-CRM(197)) and was tetanus toxoid in the third (MCC-TT). One month after the MCC vaccines, 91%-100% of children had serum bactericidal antibody (SBA) titers > or =8, and 89%-100% had a > or =4-fold increase. Geometric mean titer (GMT) increased from <4 to 215 (95% confidence interval [CI], 166-279). MCC-TT induced higher SBA GMTs (P<.001) and higher proportions with SBA > or =8 (P=.02) than did the MCC-CRM(197) vaccines. By 6 months, GMTs had decreased to 55.1 (95% CI, 40-76), but IgG antibody avidity increased (P<.001). Induction of immunologic memory was confirmed by a GMT of 1977 (range, 1535-2547) after the polysaccharide booster and a further increase in avidity. This evidence justified the use of a single dose in a catch-up immunization program for children 1-18 years old.

[1]  J. Paul,et al.  Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine. , 2000, FEMS immunology and medical microbiology.

[2]  D. Goldblatt,et al.  Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. , 1999, Vaccine.

[3]  N. Begg,et al.  Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. , 1999, The Journal of infectious diseases.

[4]  D. Granoff,et al.  Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. , 1998, JAMA.

[5]  B. Plikaytis,et al.  A Modified Enzyme-Linked Immunosorbent Assay for Measurement of Antibody Responses to Meningococcal C Polysaccharide That Correlate with Bactericidal Responses , 1998, Clinical Diagnostic Laboratory Immunology.

[6]  J. Eskola,et al.  Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. , 1998, The Journal of infectious diseases.

[7]  D. Goldblatt,et al.  Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. , 1998, The Journal of infectious diseases.

[8]  C. Fairley,et al.  Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. , 1996, The Journal of infectious diseases.

[9]  G. Carlone,et al.  Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. , 1996, JAMA.

[10]  M. Achtman,et al.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay , 1994, Journal of clinical microbiology.

[11]  C. Frasch,et al.  Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers , 1991, Infection and immunity.

[12]  J. Griffiss,et al.  IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. , 1983, Journal of immunology.

[13]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS , 1969, The Journal of experimental medicine.

[14]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS , 1969, The Journal of experimental medicine.